Another preclinical study revealed that the VEGFR inhibitor sorafenib induces vessel co-option in an orthotopic model of hepatocellular carcinoma (HCC) and that this increase in vessel co-option was associated with resistance to sorafenib70. This evidence concerns the gene KDR and hepatocellular carcinoma.